EI
GLUE icon

EAM Investors’s Monte Rosa Therapeutics GLUE Stock Holding History

EAM Investors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$736K Sell
30,416
-99,830
-77% -$1.89M 0.07% 251
2026
Q1 		$2.14M Buy
130,246
+60,209
+86% +$1.15M 0.25% 163
2025
Q4 		$1.1M Buy
+70,037
New +$944K 0.12% 200

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM Investors's GLUE Position: Q2 2026 in Review

EAM Investors reduced its Monte Rosa Therapeutics (GLUE) stake by 77% in Q2 2026, selling an estimated $1.89M and leaving 30,416 shares worth $736K. The position accounts for 0.07% of the portfolio, ranked #251.

EAM Investors first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.14M in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • EAM Investors held 30,416 shares of Monte Rosa Therapeutics worth $736K as of Q2 2026.
  • EAM Investors sold 99,830 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.89M.
  • Monte Rosa Therapeutics made up 0.07% of EAM Investors's portfolio in Q2 2026, its #251 holding.
  • EAM Investors first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • EAM Investors's Monte Rosa Therapeutics position peaked at $2.14M in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.